Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 600 shares, a decline of 94.3% from the March 31st total of 10,500 shares. Based on an average trading volume of 12,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $1.18 on Friday. The firm has a 50 day moving average of $1.77 and a 200 day moving average of $2.60. Akari Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.50.

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research note on Wednesday. They issued a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.